Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2009 1
2011 1
2012 7
2013 1
2015 1
2017 2
2018 6
2019 1
2020 2
2021 7
2022 13
2023 13
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Related Articles by Review for PMID: 37384750

44 results

Results by year

Filters applied: . Clear all
Page 1
Vericiguat.
[No authors listed] [No authors listed] 2023 Jun 16. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2023 Jun 16. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 37384750 Free Books & Documents. Review.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial.
Armstrong PW, Roessig L, Patel MJ, Anstrom KJ, Butler J, Voors AA, Lam CSP, Ponikowski P, Temple T, Pieske B, Ezekowitz J, Hernandez AF, Koglin J, O'Connor CM. Armstrong PW, et al. JACC Heart Fail. 2018 Feb;6(2):96-104. doi: 10.1016/j.jchf.2017.08.013. Epub 2017 Oct 11. JACC Heart Fail. 2018. PMID: 29032136 Free article. Review.
Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum.
Butler J, Usman MS, Anstrom KJ, Blaustein RO, Bonaca MP, Ezekowitz JA, Freitas C, Lam CSP, Lewis EF, Lindenfeld J, McMullan CJ, Mentz RJ, O'Connor C, Rosano GMC, Saldarriaga CI, Senni M, Udelson J, Voors AA, Zannad F. Butler J, et al. Eur J Heart Fail. 2022 Nov;24(11):2029-2036. doi: 10.1002/ejhf.2720. Epub 2022 Nov 16. Eur J Heart Fail. 2022. PMID: 36250238 Free article. Review.
Vericiguat for Heart Failure with Reduced Ejection Fraction.
Lombardi CM, Cimino G, Pagnesi M, Dell'Aquila A, Tomasoni D, Ravera A, Inciardi R, Carubelli V, Vizzardi E, Nodari S, Emdin M, Aimo A. Lombardi CM, et al. Curr Cardiol Rep. 2021 Aug 19;23(10):144. doi: 10.1007/s11886-021-01580-6. Curr Cardiol Rep. 2021. PMID: 34410527 Free PMC article. Review.
Vericiguat: A New Hope for Heart Failure Patients.
Chiles R, Al-Horani RA. Chiles R, et al. Cardiovasc Ther. 2022 Dec 17;2022:1554875. doi: 10.1155/2022/1554875. eCollection 2022. Cardiovasc Ther. 2022. PMID: 36618548 Free PMC article. Review.
44 results